JC

James Calloway

Financial Reporter

James Calloway is a financial reporter at StockTi covering corporate earnings, regulatory policy, and market-moving events. A former business journalist with Reuters, James has covered financial markets for over eight years across New York and Washington. He specializes in breaking down earnings reports, SEC filings, and policy decisions that affect publicly traded companies and investor portfolios.

Earnings, Regulation 1,778 articles

Articles by James Calloway

Okta Shares Slip on Tempered Growth Outlook Despite Strong Quarter
Earnings

Okta Shares Slip on Tempered Growth Outlook Despite Strong Quarter

Okta shares fell in extended trading after the company projected approximately 9% revenue growth for its upcoming fiscal year, despite reporting better-than-expected fourth-quarter results and expanding its security offerings for AI agents.

OKTA
Mondelez Appoints Danone Veteran to Lead Africa Push Amid Volume Pressures
Earnings

Mondelez Appoints Danone Veteran to Lead Africa Push Amid Volume Pressures

Mondelez International has appointed Hisham Ezz El-Arab, a former Danone executive, to lead its Sub-Saharan Africa operations. The move comes as the snack giant's Oreo brand surpasses $4 billion in global annual revenue while the company faces volume declines.

MDLZ PEP HSY SJM KHC
J&J Shares Dip on Lupus Drug Fast Track, Investors Eye Legal Risks
Regulation

J&J Shares Dip on Lupus Drug Fast Track, Investors Eye Legal Risks

Johnson & Johnson shares declined 0.7% to $245.07 Wednesday after the FDA granted Fast Track designation to its lupus drug candidate nipocalimab, lagging behind a strong market advance.

JNJ SPY MRK ABBV PFE XLV
CrowdStrike Stock Steady After Strong Forecast, ARR in Focus
Earnings

CrowdStrike Stock Steady After Strong Forecast, ARR in Focus

CrowdStrike Holdings closed nearly flat at $391.44 following a volatile session, after reporting a 23% jump in Q4 revenue and issuing a robust long-term revenue forecast that exceeded analyst expectations.

CRWD
T-Mobile Countersues Verizon in Escalating Ad War Over 'Bait-and-Switch' Claims
Regulation

T-Mobile Countersues Verizon in Escalating Ad War Over 'Bait-and-Switch' Claims

T-Mobile has launched a countersuit against Verizon, accusing its rival of 'bait-and-switch' tactics in a recent advertising campaign. The move escalates a legal fight that began when Verizon sued T-Mobile in February over alleged savings exaggerations.

TMUS VZ T
Kontoor Brands Soars on Robust 2026 Outlook Despite Tariff Headwinds
Earnings

Kontoor Brands Soars on Robust 2026 Outlook Despite Tariff Headwinds

Kontoor Brands shares jumped 21% after issuing a strong 2026 profit forecast, projecting adjusted EPS of $6.40-$6.50 and revenue up to $3.45 billion. The company anticipates over $100 million in tariff expenses but plans to offset them within 18 months.

KTB
Tesla's EU Emissions Pool Loses Key Carmakers for 2026
Regulation

Tesla's EU Emissions Pool Loses Key Carmakers for 2026

Stellantis, Toyota, and Subaru have not joined Tesla's 2026 EU carbon-credit pool, filings show, a shift from 2025. Tesla's regulatory credit revenue declined 28% to $1.99 billion last year.

TSLA STLA TM
EU's 'Made in EU' Rules Threaten Ford's Supply Chain
Regulation

EU's 'Made in EU' Rules Threaten Ford's Supply Chain

The European Commission has proposed strict 'Made in EU' rules linking subsidies to local content, potentially excluding Ford's key suppliers in Britain and Turkey. The plan faces significant opposition and requires approval.

F TM RHHBY SIEGY SAP HSBC BACHY LVMUY SSNLF AZN NVS XLE XLF XLV XLK FXI MCHI
Plug Power Soars on Q4 Profit, New CEO Outlines Liquidity Plan
Earnings

Plug Power Soars on Q4 Profit, New CEO Outlines Liquidity Plan

Plug Power shares jumped 23% following a stronger-than-expected Q4, which delivered a $5.5 million gross profit. The company also detailed plans to bolster liquidity through asset sales.

PLUG
FDA Issues Second Ozempic Ad Warning to Novo Nordisk in Escalating Scrutiny
Regulation

FDA Issues Second Ozempic Ad Warning to Novo Nordisk in Escalating Scrutiny

The FDA has sent Novo Nordisk a second advertising violation notice in under a month, citing misleading claims for Ozempic. The agency simultaneously warned 30 telehealth companies about compounded GLP-1 drug promotions.

NVO LLY XLV
Target Unveils $5B Revamp Plan Amid Sales Slump, Shares Rally
Earnings

Target Unveils $5B Revamp Plan Amid Sales Slump, Shares Rally

Target Corporation is boosting its 2026 capital spending to $5 billion, adding over 30 new stores and 130 remodels. The retailer reported a 1.5% drop in Q4 net sales but shares jumped nearly 7% on the strategic outlook.

TGT WMT AMZN
Vistry Plunges on Margin Outlook, Leadership Transition
Earnings

Vistry Plunges on Margin Outlook, Leadership Transition

Vistry Group stock tumbled more than 20% as the UK homebuilder warned of compressed margins for 2026 and revealed its executive chair will step down, with debt reduction taking priority over shareholder returns.

EWU